医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Herbalife Receives Approval for Additional Direct-Selling License in China

2013年08月08日 PM09:25
このエントリーをはてなブックマークに追加


 

LOS ANGELES

Global nutrition company, Herbalife (NYSE: HLF), announced today that China’s Ministry of Commerce has granted a license for Herbalife to conduct its direct-selling business in the province of Yunnan. The licensed area in Yunnan province covers 12 cities, including the provincial capital Kunming, and 16 districts and counties. The license is effective immediately.

Herbalife received its first direct-selling license in China in March 2007, and Yunnan marks the 25th direct selling license for Herbalife in this important market. Herbalife China now has direct-selling licenses in 25 provinces, municipalities or autonomous regions: Shanghai, Jiangsu, Hubei, Anhui, Shangdong, Henan, Zhejiang, Sichuan, Chongqing, Fujian, Hunan, Guangdong, Jiangxi, Hainan, Guizhou, Guangxi, Liaoning, Jilin, Heilongjiang, Shaanxi, Beijing, Shanxi, Tianjin, Hebei and Yunnan.

About Herbalife Ltd.

Herbalife Ltd. (NYSE:HLF) is a global nutrition company that sells weight-management, nutrition and personal care products intended to support a healthy lifestyle. Herbalife products are sold in more than 80 countries to and through a network of independent distributors. The company supports the Herbalife Family Foundation and its Casa Herbalife program to help bring good nutrition to children. Herbalife’s website contains information about Herbalife, including financial and other information at www.herbalife.com.

CONTACT

Herbalife Ltd.
Media Contact:
Julian
Cacchioli, 213-745-0519
or
Investor
Contact:

Amy Greene, 213-745-0504

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • アスターDMヘルスケア、25万米ドル相当の世界看護賞を発表
  • Prestige BioPharma Enters MOU with Busan City for Establishment of its R&D Centre in Busan, South Korea
  • Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59)
  • InnoCare Announces Approval of Clinical Trial of TYK2 Inhibitor ICP-332 in China
  • 患者安全运动基金会公布参加首届医疗安全研究员项目五人名单